Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer
Open Access
- 10 September 2021
- journal article
- Published by Herald Scholarly Open Access in Journal of Stem Cells Research, Development & Therapy
- Vol. 7 (3), 1-9
- https://doi.org/10.24966/srdt-2060/100076
Abstract
Disease recurrence and progression of ovarian cancer is a common event, which is accompanied by the development of platinum-resistant or refractory disease. The presence of chemo-resistant Cancer Stem Cells (CSCs) contribute to tumor propagation, maintenance, and treatment resistance of this difficult to treat disease.Keywords
This publication has 46 references indexed in Scilit:
- Complexity of cancer stem cellsInternational Journal of Cancer, 2012
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerJournal of Clinical Oncology, 2012
- Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian CancerMolecular Cancer Therapeutics, 2010
- Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2010
- Rapid Selection and Proliferation of CD133(+) Cells from Cancer Cell Lines: Chemotherapeutic ImplicationsPLOS ONE, 2010
- Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: One institution's experienceWorld Journal of Gastroenterology, 2008
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003
- The Subrenal Capsule Assay in Selecting Chemotherapy for Ovarian Cancer: A Prospective Randomized TrialGynecologic Oncology, 1995
- Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary culturesAnti-Cancer Drugs, 1995
- A southwest oncology group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancerCancer, 1991